股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/ ...

Group 1 - The stock of Kunbo Medical-B (02216.HK) increased by nearly 10%, reaching a price of 2.65 HKD per share [2] - As of the report, the stock was up by 9.96% with a trading volume of 3.29 million HKD [2]

Core Viewpoint - Kubo Medical-B (02216) shares rose nearly 10%, currently up 9.96% at HKD 2.65, with a trading volume of HKD 3.29 million [1] Group 1: Product Development and Regulatory Approvals - Kubo Medical announced that its BroncTarget lung-targeted radiofrequency ablation system has entered the special review process for innovative medical devices by the National Medical Products Administration of China, indicating recognition of its core technology originality and clinical value [1] - The confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [1] Group 2: Market Expansion and Product Launches - Kubo Medical's self-developed BroncAblate intelligent lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch in Hong Kong as the world's first natural orifice radiofrequency ablation device for lung cancer intervention [1] - Concurrently, the FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered by the Hong Kong Department of Health [1] - The BroncTru single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]

Core Viewpoint - KPB Medical-B (02216) has seen a nearly 10% increase in stock price, currently trading at 2.65 HKD, following the announcement of significant regulatory advancements for its medical devices [1] Group 1: Regulatory Approvals - KPB Medical announced that its BroncTarget® lung-targeted radiofrequency ablation system has entered the special review process by the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology and clinical value [1] - The BroncTarget® system is currently undergoing confirmatory clinical trials, with 28 hospitals across the country actively recruiting participants [1] Group 2: Product Launches - The BroncAblate® Smart® lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch as the world's first natural orifice radiofrequency ablation device for lung cancer [1] - The FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered with the Hong Kong Department of Health [1] - The BroncTru® single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]

Core Insights - The BroncTarget lung-targeted denervation radiofrequency ablation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology originality and clinical significance [1] - Targeted Lung Denervation (TLD) is a breakthrough intervention technique for moderate to severe Chronic Obstructive Pulmonary Disease (COPD), aiming to suppress airway abnormal contraction and mucus hypersecretion [1] - The BroncTarget system employs innovative designs such as circular multi-electrodes, adjustable orifices, differentiated output of radiofrequency energy, real-time monitoring of temperature and impedance, and intelligent saline infusion to ensure ablation efficiency and safety [1] Clinical Trials - Confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [2]

Core Viewpoint - The BroncTarget® lung denervation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its innovative technology and clinical value [1] Group 1: Product Overview - The BroncTarget® system is a targeted lung denervation technology aimed at treating moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1] - It utilizes a bronchoscopic approach to deliver radiofrequency energy precisely to nerve targets, aiming to suppress airway hypercontraction and mucus hypersecretion [1] - The system offers a new treatment option for patients whose symptoms remain poorly controlled despite conventional drug therapy, integrating an "intervention + medication" management strategy [1] Group 2: Technological Features - The BroncTarget® system features innovative designs such as circular multi-electrodes, adjustable orifices, differentiated radiofrequency energy output, real-time temperature and impedance monitoring, and intelligent saline infusion [1] - These features ensure the efficiency and safety of radiofrequency ablation [1] Group 3: Clinical Trials - Confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted simultaneously across 28 hospitals nationwide [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Broncus Holding Corporation 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） 本公告由堃博醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）在 自願的基礎上發佈，旨在將本集團業務發展的最新情況告知本公司股東及潛在投 資者。 本公司的董事（「董事」）會（「董事會」）欣然宣佈，旗下BroncTarget®肺部靶向去神 經射頻消融系統（以下簡稱「BroncTarget®系統」）正式進入中國國家藥品監督管理 局（「國家藥監局」）的創新醫療器械特別審查程序（國家藥監局公示文件中披露產 品名為：「肺部射頻消融系統」），標誌着該產品在核心技術原創性、臨床價值顯著 性等方面獲得國家藥監部門的認可。 肺部靶向去神經射頻消融(Targeted Lung Denervation，TLD)是一項針對中重度慢 性阻塞性肺疾病（慢阻肺，Chronic Obstructive Pulm ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 526,579,084 | | 1,658,000 | | 528,237,084 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 526,579,0 ...

Core Viewpoint - Company Kubo Medical-B (02216) plans to acquire 157,800 shares of Series B preferred stock of Valgen Holding Corporation for $15 million, representing 1.05% of the target company's fully diluted shares as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made through Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation specializes in providing systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly™ mitral valve repair device and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to establish a comprehensive diagnostic and treatment platform for cardiopulmonary diseases, given the similarities and connections between structural heart diseases and pulmonary diseases [1] - The collaboration is expected to leverage the company's expertise in chronic obstructive pulmonary disease (COPD) to strengthen the foundation for a comprehensive cardiopulmonary diagnostic and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities by applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]

Core Viewpoint - Company Kubo Medical-B (02216) announced the acquisition of 157,800 shares of Series B preferred stock in Valgen Holding Corporation for a total consideration of $15 million, representing 1.05% of the target company's fully diluted and converted shares outstanding as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made by Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation primarily provides systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly mitral valve repair device (via the transvenous approach) and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity for the company to achieve comprehensive diagnosis and treatment of cardiopulmonary diseases, given the similarities and correlations between structural heart diseases and pulmonary diseases [1] - The collaboration with Valgen will leverage the company's expertise in chronic obstructive pulmonary disease to establish a solid foundation for a comprehensive cardiopulmonary diagnosis and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities, applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]